Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-24T00:59:06.816Z Has data issue: false hasContentIssue false
  • English
  • Français

Medication Use in the Seniors Population: Optimization of Physician Prescribing as a Means of Preventing Drug-related Illness

Published online by Cambridge University Press:  08 November 2023

Robyn Tamblyn
Robyn Tamblyn*
Affiliation:
McGill University
*
Requests for reprints should be sent to:/Les demandes de reproduction doivent être adressées à: Robyn Tamblyn, Division of Clinical Epidemiology, McGill University, Royal Victoria Hospital, 687 Pine Avenue West R4.29, Montreal, PQ H3A 1A1
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Drug-related illness (DRI) is a common problem in the elderly. Misuse of medications and inappropriate prescribing account for over half of all hospital admissions for DRI and both are potentially preventable. Physicians are the gatekeepers to prescription medication access and, in this role, they have the opportunity to prevent exposure to unnecessary and inappropriate medication and influence the use of medications by their elderly patients. Effective interventions to improve physician prescribing have been identified but they are costly to introduce, they require ongoing maintenance to maintain their effectiveness, they do not address the problems created by multiple prescribers or the challenges of keeping up-to-date on the growing number of new drugs that enter the market each year. Computer-based drug information networks and expert decision-making support systems are proposed as one means of providing (1) an accurate record for the prescribing physicians of drugs currently dispensed to their elderly patients, (2) a review of problems in existing and new prescriptions, and (3) an expert resource to select drug treatment. Canada is in an ideal situation to pioneer the development of these systems, but to do so, policies need to be put in place to address three problems. First, there is inadequate information available about the risks and benefits of drugs in the elderly because older sicker adults are often excluded in clinical trials of drug-effectiveness. Requirements for drug approval need to be amended so that sufficient evaluation of the risks and benefits of new drugs are carried out in the elderly. Second, computerization in the health care sector is central to the development of electronic decision-support systems in health care delivery. Future policy needs to be directed to the development of an effective infrastructure to facilitate the transition to an integrated computerized health sector. Third, the ethical and legal issues related to the access of prescription data through electronic networks need to be identified and clear guidelines for use of this new technology need to be developed.

Résumé

Résumé

Les maladies reliées aux médicaments (MRM) sont fréquentes chez les aînés. La mauvaise utilisation des médicaments et la prescription d'ordonnances potentiellement non appriopriées (OPNA) sont responsables de plus de la moitié des admissions hospitalières reliées aux MRM. Ceci pourrait être évité. Les médecins contrôlent l'accés aux médicaments d'ordonnance. Ils peuvent done prévenir I'exposition des patients agés aux médicaments inutiles et aux OPNA, et influer sur l'utilisation des medicaments par leurs patients. On a identifié certaines interventions efficaces pour améliorer les habitudes de prescription chez les médecins. Mais leur implantation est coûteuse. Elles doivent être maintenues de façon continue pour conserver leur efficacité. Elles sont inopérantes sur les OPNA généres par des prescripteurs multiples. Elles ne permettent pas au médecin de rester a jour sur le nombre croissant de médicaments qui font leur entrée sur le marché chaque année. On propose ici d'utiliser les technologies informatiques de réseautage et d'aide à la décision pour offrir aux médecins prescripteurs (1) des informations précises et actualisées sur les médicaments dispensés à leurs patients ages, (2) une revue des problèmes médicamenteux existants et de ceux créés par de nouvelles ordonnances et (3) des conseils d'experts sur le choix d'un traitement médicamenteux. Le Canada est dans une position idéale pour devenir un pionnier dans le développement de tels systémes. Mais il faudrait d'abord mettre en place certaines politiques pour régler trois problèmes. Premièrement, l'information disponible sur les risques et les benefices des médicaments chez les aînés est inadequate car les personnes âgées «les plus malades» sont souvent excluses des essais cliniques. Les prérequis à l'approbation des medicaments doivent être amendés afin de permettre une évaluation satisfaisante des risques et des bénéfices des nouveaux medicaments chez les aînés. Deuxièmement, l'informatisation du système de santé est primordiale dans le développement d'outils informatiques d'aide à la décision pour la dispensation des soins. Les politiques futures devraient favoriser le developpement d'une infrastructure efficace si Ton veut faciliter la transition vers un système de santé informatisé et intégré. Troisièmement, les questions de nature éthiques et légales reliées à l'accés des données de consommation des médicaments via les réseaux informatiques doivent être identifiers. Des règies de conduite claires sur l'utilisation des nouvelles technologies doivent être développees.

Keywords

ElderlyPrescribingPhysician PracticeDrug-related IllnessAinésprescriptionpratique de la médecinemaladie liée aux medicaments
Type
Research Article
Information
Canadian Journal on Aging / La Revue canadienne du vieillissement , Volume 16 , Issue S1: Bridging Policy and Research on Aging/Tisser des liens entre les politiques et la recherche relative au vieillissement , Spring Printemps 1997 , pp. 147 - 161
Copyright
Copyright © Canadian Association on Gerontology 1997

Footnotes

*

This paper is a contribution of the Quebec Research Group on Medication Use in the Elderly (USAGE), funded by Health Canada's Seniors Independence Research Program.

References

Nolan, L., O'Malley K. Prescribing for the elderly, part 1: Sensitivity of the elderly to adverse drug reactions. Journal of American Geriatrics Society 1988; 36:142-9.CrossRefGoogle Scholar
Karch, F.E., Lasagna L. Adverse drug reactions: a critical review. Journal of the American Medical Association 1975; 234:1236-41.CrossRefGoogle Scholar
Quinn, K., Baker, M.J., Evans B. A population-wide profile of prescription drug use in Saskatchewan. Canadian Medical Association Journal 1992; 146:2177-86.Google Scholar
Bero, L.A., Lipton, H.L., Bird, J.A.. Characterization of geriatric drug-related hospital readmissions. Medical Care 1991; 29(10):989-1003.CrossRefGoogle Scholar
Grymonpre, R.E., Mitenko, P.A., Sitar, D.S., Aoki, F.Y., Montgomery, P.R.. Drug-associated hospital admissions in older medical patients. Journal of the American Geriatrics Society 1988; 36:1092-8.CrossRefGoogle Scholar
Col, N., Fanale, J.E., Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Archives of Internal Medicine 1990; 150:841-5.CrossRefGoogle Scholar
Hallas, J., Gram, L.F., Grodum, E., Damsbo, N., Brosen, K., Haghfelt, T., Harvald, B., Beck-Nielsen, J., Worm, J., Birger Jensen, K., Davidsen, O., Franssen, N.E., Hagen, C., Andersen, M., Frolund, F., Kromann-Andersen, H., Schol, J.,. Drug related admissions to medical wards: a population based survey. British Journal of Clinical Pharmacology 1992; 33:61-68.CrossRefGoogle Scholar
Ferguson, J.A.. Patient age as a factor in drug prescribing practices. Canadian Journal on Aging 1990; 9:278-95.CrossRefGoogle Scholar
Shorr, R.I., Bauwens, S.F., Landefeld, C.S.. Failure to limit quantities of benzodiazepine hypnotic drugs for outpatients: placing the elderly at risk. American Journal of Medicine 1990; 89:725-32.CrossRefGoogle Scholar
Brook, R.H., Kamberg, C.J., Mayer-Oakes, A., Beers, M.H., Raube, K., Steiner A. Appropriateness of acute medical care for the elderly. Santa Monica, CA: RAND Corporation, 1989.CrossRefGoogle Scholar
Tamblyn, R.M., McLeod, P., Abrahamowicz, M., Monette, J., Gayton, D.C., Berkson, L., Dauphinee, W.D., Grad, R.M., Huang, A.R., Isaac, L.M., Schnarch, B.S., Snell, L.S.. Questionable prescribing for elderly patients in Quebec. Canadian Medical Association Journal 1994; 150:1801-9.Google Scholar
Ives, T.J., Bentz, E.J., Gwyther, R.E.. Drug-related admissions to a family medicine inpatient service. Archives of Internal Medicine 1987; 147:1117-20.CrossRefGoogle Scholar
Colt, H.G., Shapiro, A.P.. Drug-induced illness as a cause for admission to a community hospital. Journal of the American Geriatrics Society 1989; 37:323-6.CrossRefGoogle Scholar
Larson, E.B., Kukull, W.A., Buchner, D., Reifler, B.V.. Adverse drug reactions associated with global cognitive impairment in elderly persons. Annals of Internal Medicine 1987; 107:169-73.CrossRefGoogle Scholar
MacDonald, J.B., MacDonald, E.T.. Nocturnal femoral fracture and continuing widespread use of barbituate hypnotics. British Medical Journal 1977; 2:483-5.CrossRefGoogle Scholar
Ray, W.A., Griffin, M.R., Schaffner, W., Baugh, D.K., Melton, L.J.. Psychotropic drug use and the risk of hip fracture. New England Journal of Medicine 1987; 316:363-9.CrossRefGoogle Scholar
Hansten, P., Horn J. Drug interactions (6th ed.) Philadelphia: Lea & Febiger, 1989.Google Scholar
Schrier, R.W.. Renal and electrolyte disorders (4th ed.) City: Little Brown & Co., 1993.Google Scholar
Anon. Drugs for hypertension. Medical Letter on Drugs and Therapeutics 1993; 35:55-60.Google Scholar
Kearney, T.E., Manoguerra, A.S., Curtis, G.P., Ziegler, M.G.. Theophylline toxicity and the beta-adrenergic system. Annals of Internal Medicine 1985; 102:766-9.CrossRefGoogle Scholar
Lombardi, T.P., Bertino, J.S., Goldberg, A., Middleton, E., Slaughter, R.L.. The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. Journal of Clinical Pharmacology 1987; 27:523-9.CrossRefGoogle Scholar
Corsi, C., Nafziger, A.N., Pieper, J.A., Bertino J. Lack of effect of atenolol and nadolol on the metabolism of theophylline. British Journal of Clinical Pharmacology 1990; 29:265-8.CrossRefGoogle Scholar
Miners, J.O., Wing, M.H., Lillywhite, K.J., Robson, R.A.. Selectivity and dose-dependency of the inhibitory effect of propranolol on theophylline metabolism in man. British Journal of Clinical Pharmacology 1985; 20:219-23.CrossRefGoogle Scholar
Anon. Aspirin and bleeding. Journal of the American Medical Association 1971; 218:89.CrossRefGoogle Scholar
Anon. Aspirin and gastrointestinal bleeding. Journal of the American Medical Association 1969; 207:2430.CrossRefGoogle Scholar
DiTomasso, R.A., Willard M. The development of a patient satisfaction questionnaire in the ambulatory setting. Family Medicine 1991; 23(2): 127-31.Google Scholar
Trunet, P., Le Gall, J.R., Lhoste, F., Regnier, B., Saillard, Y., Carlet J. The role of iatrogenic disease in admissions to intensive care. Journal of the American Medical Association 1980; 244:2617-20.CrossRefGoogle Scholar
Tilstone, W.J., Gray, J.M.. Interaction between warfarin and sulphamethoxazole. Postgraduate Medical Journal 1977; 53:388-90.CrossRefGoogle Scholar
Loeliger, E.A. et al. The biological disappearance rate of prothrombin and factors VII, IX and X from plasma in hypothyroidism, hyperthyroidism and during fever. Trombosis et Diathesis Haemorrhagica 1964; 10:267.Google Scholar
Hassall, C., Feetam, C.L., Leach, R.H., Meynell, M.J.. Potentiation of warfarin by co-trimoxazole. Lancet 1975; 2:1155-6.CrossRefGoogle Scholar
Kaufman, J.M., Fauver, H.E. Jr. Potentiation of warfarin by trimethoprimsulfamethoxazole. Urology 1980; 16:601-3.CrossRefGoogle Scholar
Errick, J.K., Keys, P.W.. Co-trimoxazole and warfarin: case report of an interaction. American Journal of Hospital Pharmacy 1978; 35:1399-401.Google Scholar
Lumholtz, B., Siersbaek-Nielsen, K., Skovsted L. Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism. Clinical Pharmacology & Therapeutics 1975; 17:731-4.CrossRefGoogle Scholar
Anton, A.H.. Increasing activity of sulfonamides with displacing agents: A review. Annals of the New York Academy of Sciences 1973; 226:73.CrossRefGoogle Scholar
Ray, M.A., Griffin, M.R., Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. Journal of the American Medical Association 1989; 262:3303-7.CrossRefGoogle Scholar
Levy, A.R., Mayo, N.E., Grimard G. Rates of transcerical and pertrochanteric hip fractures in the province of Quebec, Canada, 1981-1992. American Journal of Epidemiology 1995; 142:428-36.CrossRefGoogle Scholar
Tamblyn, R.M., McLeod, P.J., Abrahamowicz, M., Laprise R. Do too many cooks spoil the broth? Multiple physician involvement in medical management and inappropriate prescribing in the elderly. Canadian Medical Association Journal 1996; 154:1177-84.Google Scholar
Woods, J.H., Katz, J.L., Winger G. Benzodiazepines: use, abuse, and consequences. Pharmacology Reviews 1992; 44:151-337.Google Scholar
Anon. National pharmaceutical strategy discussion document. The National Pharmaceutical Strategy Office, Drugs Directorate, Health Protection Branch 1993.Google Scholar
Riga A. Rx for Safety: Software warns if prescriptions are dangerous. The Gazette 1993; July. Business Sec.D.Google Scholar
Kaufman, M., Uhlman M. Electronic 2d opinion targets Rxs of ages. The Philadelphia Inquirer 1993; July Section A.Google Scholar
Tamblyn, R.M., Battista, R.N.. Changing clinical practice: which interventions work? The Journal of Continuing Education in the Health Professions 1993; 13:273-88.CrossRefGoogle Scholar
Avorn, J., Soumerai, S.B.. Improving drug-therapy decisions through educational outreach: a randomized controlled trial of academically based "detailing". New England Journal of Medicine 1983; 308:1457-63.CrossRefGoogle Scholar
Soumerai, S.B., McLaughlin, T.J., Avorn J. Quality assurance for drug prescribing. Quality Assurance in Health Care 1990; 2:37-58.CrossRefGoogle Scholar
Soumerai, S.B., Avorn J. Economic and policy analysis of university-based drug "detailing". Medical Care 1986; 24:313-31.CrossRefGoogle Scholar
Soumerai, S.B., McLaughlin, T.J., Avorn J. Improving drug prescribing in primary care: a critical analysis of the experimental literature. The Milbank Quarterly 1989; 67:268-317.CrossRefGoogle Scholar
Beers, M.H., Storrie, M., Lee G. Potential adverse drug interactions in the emergency room. Annals of Internal Medicine 1990; 112:61-64.CrossRefGoogle Scholar
Muijen, M., Silverstone T. A comparative hospital survey of psychotropic drug prescribing. British Journal of Psychiatry 1987; 150:501-4.CrossRefGoogle Scholar
Wilcox, S.M., Himmelstein, D.U., Woolhandler S. Inappropriate drug prescribing for the community-dwelling elderly. Journal of the American Medical Association 1994; 272:292-6.CrossRefGoogle Scholar
Bloom, J.A., Frank, J.W., Shafir, M.S., Martiquet P. Potentially undesirable prescribing and drug use among the elderly: measurable and remediable. Canadian Family Physician 1993; 39:2337-45.Google Scholar
Beers, M.H., Ouslander, J.G., Fingold, S.F., Morgenstern H. Inappropriate medication prescribing in skilled-nursing facilities. Annals of Internal Medicine 1992; 117:684-9.CrossRefGoogle Scholar
Maronde, R.F., Lee, P.V., McCarron, M.M., Seibert S. A study of prescribing patterns. Medical Care 1971; 9:383-95.CrossRefGoogle Scholar
Kroenke K. Polypharmacy : causes, consequences, and cure. American Journal of Medicine 1985; 79:149-52.CrossRefGoogle Scholar
Gurwich, E.L.. Comparison of medication histories acquired by pharmacists and physicians. American Journal of Hospital Pharmaceuticals 1983; 40:1541-2.Google Scholar
Kendrick, R., Bayne, J.R.D.. Compliance with prescribed medication by elderly patients. Canadian Medical Association Journal 1982; 127:961-2.Google Scholar
Monette, J., Tamblyn, R.M., McLeod, P., Gayton, D., Abrahamowicz, M., Berkson, L., Dauphinee, D., Grad, R., Huang, A., Sampalis, J., Schnarch, B., Snell L. Profile of long-acting benzodiazepine drug prescribing. Journal of Clinical Investigative Medicine 1993; 16s 4:B59.Google Scholar
Schnarch, B., Tamblyn, R.M., McLeod P. Psychotropic drug prescribing in the elderly: exploration of the patient gender-physician gender relationship. The Canadian Pharmacoepidemiology Forum 1993; Toronto: (abstract)Google Scholar
Tamblyn, R.M., Abrahamowicz, M., Berkson, L., Dauphinee, D., Gayton, D., Grad, R., Mcleod, P., Isaac, L., Snell L. The feasibility of using standardized patients to measure the medical management of high risk prescribing situations in the elderly. Final Report, NHRDP Project #6605-3752-57P 1993.Google Scholar
Tamblyn, R.M., Lavoie, G., Terella, L., Monette J. The use of prescription claims databases in pharmacoepidemiological research: The accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiology, 1995, 48(8):999-1009.CrossRefGoogle Scholar
Ministry of Health. Health network: A new service for your health and safety. Health Network ISBN 0-7778-3003-5 Cat #2127399 Queen's Printer for Ontario 1994.Google Scholar
Johnston, M.E., Langton, D.B., Haynes, B., Mathieu A. Effects of computer-based clinical decision support systems on clinician performance and patient outcome. Annals of Internal Medicine 1994; 120:135-42.CrossRefGoogle Scholar
Grimshaw, J.M., Russell, I.T.. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993; 342:1317-22.CrossRefGoogle Scholar
Lindley, C.M., Tully, M.P., Paramsothy, V., Tallsi, R.C.. Inappropriate medication is a major cause of adverse drug reactions in elderly patients. Age and Ageing 1992; 21:294-300.CrossRefGoogle Scholar
Canarie Inc. Towards a Canadian health way: Vision, opportunities and future steps. Canarie Inc, Ottawa, September 27, 1996.Google Scholar
Gurwitz, J.H., Col, N.F., Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA,1992, 268(ll):1417-22.CrossRefGoogle Scholar